Key Highlights
● Atomera reported no Revenue for the quarter ended Sept. 30, 2026.
● The net loss widened slightly to $6.0 million, or $0.15 per share.
● Cash and short-term investments reached $34.8 million, up from $19.2 million at year-end.
● A joint development agreement with IQE covers radio-frequency gallium nitride.
Atomera Incorporated (NASDAQ:ATOM), which licenses its Mears Silicon Technology (MST) materials process to semiconductor makers, remains a pre-commercial company whose value rests on future licensing and Royalty income. Two details from its third-quarter report, released Oct. 29, 2026, stand out for investors assessing how long it can keep pursuing that goal: a cash balance that has nearly doubled since the start of the year, and a new joint development agreement with compound semiconductor wafer supplier IQE covering radio-frequency gallium nitride (GaN). Both developments relate to the same underlying question of runway and commercial traction.
Latest Company Context
For the quarter ended Sept. 30, 2026, Atomera reported no revenue, compared with $11,000 a year earlier; revenue for the first nine months totaled $169,000. The net loss widened slightly to $6.0 million, or $0.15 per share, from $5.6 million, or $0.17 per share, with the lower per-share loss reflecting a larger share count. Operating expenses were $6.3 million for the quarter and $19.4 million for nine months. Cash, cash equivalents and short-term investments stood at $34.8 million on Sept. 30, up from $19.2 million on Dec. 31, 2025. The company also said its gate-all-around (GAA) engagements had grown to three customers. The nine-month net loss totaled $18.4 million, or $0.49 per share. The release also noted a demonstration of a simpler, lower-cost approach to next-generation DRAM transistors using MST.
Key Business and index Drivers
The Balance Sheet is a key consideration because Atomera's licensing model has so far produced only small, irregular revenue. At the recent quarterly Operating Expense run rate of roughly $6 million, the September cash position could cover several more quarters of spending, although actual needs depend on hiring, engineering work and any customer-funded programs. The rise in cash alongside a higher share count suggests Equity issuance played a role, so dilution remains part of the picture.
On the technology side, the IQE agreement extends MST into GaN-on-silicon, a material used in RF and power devices, and the company described it as a step toward commercialization in that area. Atomera also reported progress in DRAM transistor work and interest from GAA foundries in its diffusion-blocking capability. Converting engagements into signed production licenses, which generate royalties, is the milestone the business model ultimately requires, and its timing remains uncertain.
What Investors Should Watch
Investors may watch for any announcement that a development engagement has moved to a production or Manufacturing license, since royalty-bearing agreements would be a clearer validation of the technology than evaluations alone. Updates on the IQE collaboration, such as test results or customer sampling of GaN-on-silicon wafers, could also be informative. The fourth-quarter and full-year 2026 report, likely in early 2027 based on past timing though not yet scheduled, should show year-end cash and full-year spending. Any commentary on 2027 operating expense plans, financing activity or new GAA and memory customers would help investors gauge both runway and commercial momentum. Broader semiconductor Capital spending trends may also influence how quickly chipmakers adopt new materials processes. Any updates on the three GAA engagements, including whether they progress beyond evaluation, may also be closely followed.
Runway First, Royalties Later
Atomera's latest quarter combined zero revenue with a stronger cash position and an expanded set of partnerships. That mix keeps the company's story focused on technical validation and the eventual signing of royalty-bearing licenses. Investors may weigh the improved runway against continuing losses, potential dilution and the uncertain timing of commercial adoption when assessing the company's progress. The IQE agreement adds a new application area, but its commercial value has yet to be demonstrated. Execution over the next several quarters may therefore matter more than any single announcement.

_11_16_2026_14_11_57_237005.jpg)




Please wait processing your request...